Navigation Links
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Date:9/17/2007

t

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACTS:

For Genta Incorporated

Tara Spiess

TS Communications Group, LLC

(908) 286-3980

info@genta.com


'/>"/>
SOURCE Genta Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
7. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
8. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... -- In people with sex addiction, pornography affects the ... in drug addicts as they consume drugs, a new ... activity between patients who have compulsive sexual behavior and ... study author Dr. Valerie Voon, of the University of ... Voon,s research involved 19 men with sex addiction ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... The report “Probiotics Market by Products ... Applications (Regular, Therapeutic, Preventive Health Care) & Ingredients ... to 2019 ” defines and segments the global ... the market value of probiotic products and ingredients. ... factors for the global market with an analysis ...
(Date:7/11/2014)... to a new market research report “Internet of Things ... Bluetooth, Wi-Fi, NFC, RFID), Application Vertical (Building Automation, Consumer, ... - Global Trends & Forecasts to 2014 - 2020”, ... $1029.5 Billion in 2013, and is expected to reach ... 4.08% from 2014 to 2020. , Browse more ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... , , IRVING, Texas, Aug. 14 ... today that it will highlight several new products for first responders ... August 16 - 19 at the Las Vegas Convention Center. , ... - Hybrid IP25(TM) and IP25 Freedom Tracker(TM) - that will provide ...
... little impact on cognition, study finds , FRIDAY, Aug. ... no difference in mental decline after the age of ... in the Aug. 1 issue of the American ... and background have an impact on cognitive functioning among ...
... Fla., Aug. 14 Kidz-Med, Inc. (the Company), a subsidiary of ... in the distribution channels of its flagship product, the Kidz-Med Thermofocus. ... Walgreens, intent to cut many SKUs out of their planograms going ... Company,s knowledge, this decision is solely the retailer,s and is based ...
... , Visit by Lung Cancer Alliance ... WASHINGTON, Aug. 14 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) ... as a cosponsor of a bill to establish the first ever multi-agency, ... http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) , , Entitled ...
... ... on clinical performance according to Thomson Reuters, a leading provider of information and solutions to ... ... has been named one of the nation,s top 10 health systems based on clinical ...
... , EDINA, Minn., Aug. 14 ... blood glucose meter test strips do not use GDH-PQQ (glucose dehydrogenase ... glucose results in patients who are using certain therapeutic products. , ... products use a glucose-specific enzyme and can, therefore, distinguish between glucose ...
Cached Medicine News:Health News:EF Johnson Technologies, Inc. Highlights New Products at APCO 2009 2Health News:EF Johnson Technologies, Inc. Highlights New Products at APCO 2009 3Health News:Rich, Poor See Similar Declines in Old Age 2Health News:Child Health and Safety Product Distribution Channel Changes 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 3Health News:Advocate Named One Of The Nation's Top 10 Health Systems 2Health News:Advocate Named One Of The Nation's Top 10 Health Systems 3Health News:ARKRAY Statement Regarding U.S. Food and Drug Administration's Public Health Notification: Potentially Fatal Errors With GDH-PQQ Glucose Monitoring Technology 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: